Jan Danser studied pharmacy at the University of Amsterdam. In 1985, as a student, he worked at the Mayo Clinic, Rochester, USA, under the guidance of professor Paul Vanhoutte. After obtaining his pharmacist’s degree, he joined the Department of Internal Medicine at the Erasmus MC in Rotterdam as a PhD student. He defended his thesis in 1992 (promotor: professor Maarten Schalekamp), and then joined the Department of Pharmacology at the Erasmus MC. He currently is Professor of Pharmacology and heads the Division of Pharmacology within the Department of Internal Medicine at the Erasmus MC. His research focuses on the pathogenesis and therapy of hypertension, with special emphasis on the renin-angiotensin-aldosterone system, its local function(s) and the synthesis of its components at tissue sites. He has supervised >70 PhD students. In addition, he teaches pharmacology as well as pharmacotherapy. He has published >580 papers in internationally refereed journals, and he has presented >280 invited lectures worldwide. He currently is the treasurer of the European Society of Hypertension Scientific Council.

Ulrike Muscha Steckelings is a Professor of Pharmacology at the University of Southern Denmark, Odense, Denmark. She received her MD from the University of Heidelberg, Germany and worked as PostDoc at the Dept. of Pharmacology, University of Heidelberg, the Dept. of Medicine, University of Melbourne, Australia, and the Dept. of Cardiovascular Research, Ciba Geigy, Bale, Switzerland. Muscha has a specialisation in Dermatology and a PhD (Habilitation) in Experimental Pharmacology from Charité – Medical Faculty, Berlin, Germany. Muscha is an internationally renowned expert on the angiotensin AT2-receptor (AT2R) and has performed a broad spectrum of investigations related to the AT2R ranging from studies on receptor pharmacology and signalling to studies in preclinical disease models and involvement in the clinical development of the angiotensin AT2-receptor agonist C21. Her work has significantly contributed to laying the groundwork for the clinical development of C21, which is currently being tested in a Phase IIb clinical trial in idiopathic pulmonary fibrosis. Muscha is Past-President of the European Council for Cardiovascular Research, member of the Council of the International Society of Hypertension, Chair of the 2026 International Renin Angiotensin Aldosterone Conference, and member of the Editorial Board of Hypertension. Muscha has been an invited speaker at international conferences on multiple occasions and is author of more than 125 peer-reviewed publications.

A/Professor Jun Yang is the Head of the Endocrine Hypertension Group at Hudson Institute of Medical Research, a Consultant Endocrinologist at Monash Health, and a Senior Researcher in the Department of Medicine at Monash University, Victoria, Australia. Jun graduated from Monash University with a MBBS (Hon) in 2001, attained her FRACP in 2010, and completed a PhD in 2013 focusing on tissue-selective coregulators of the mineralocorticoid receptor (MR). She has since advanced basic and clinical research in the field of MR-driven cardiovascular disease, particularly primary aldosteronism, contributing to 131 original publications. She established Victoria’s first Endocrine Hypertension Service, co-leads the Primary Aldosteronism Centre of Excellence, and enjoys fostering national and international collaborations to enhance the detection and management of primary aldosteronism for better patient outcomes.